Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:POAI NYSE:RVP NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.39$0.49$0.35▼$1.22$24.51M1.39255,872 shs101,833 shsPOAIPredictive Oncology$7.08-1.9%$6.67$0.71▼$16.54$24.03M1.35473,545 shs76,012 shsRVPRetractable Technologies$0.73$0.68$0.60▼$1.14$21.86M1.2269,783 shs9,591 shsXAIRBeyond Air$0.47$0.45$0.33▼$4.78$6.74M0.22299,096 shs183,522 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents0.00%+7.73%-20.08%-33.10%-61.00%POAIPredictive Oncology0.00%-1.12%-12.92%+73.96%-43.43%RVPRetractable Technologies0.00%+4.67%+10.64%+6.90%+13.62%XAIRBeyond Air0.00%-5.45%+3.98%-34.05%-86.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.39$0.49$0.35▼$1.22$24.51M1.39255,872 shs101,833 shsPOAIPredictive Oncology$7.08-1.9%$6.67$0.71▼$16.54$24.03M1.35473,545 shs76,012 shsRVPRetractable Technologies$0.73$0.68$0.60▼$1.14$21.86M1.2269,783 shs9,591 shsXAIRBeyond Air$0.47$0.45$0.33▼$4.78$6.74M0.22299,096 shs183,522 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents0.00%+7.73%-20.08%-33.10%-61.00%POAIPredictive Oncology0.00%-1.12%-12.92%+73.96%-43.43%RVPRetractable Technologies0.00%+4.67%+10.64%+6.90%+13.62%XAIRBeyond Air0.00%-5.45%+3.98%-34.05%-86.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,278.21% UpsidePOAIPredictive Oncology 1.00SellN/AN/ARVPRetractable Technologies 0.00N/AN/AN/AXAIRBeyond Air 2.33Hold$10.002,036.75% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, POAI, CTSO, and RVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026XAIRBeyond Air Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M0.66N/AN/A$0.09 per share4.33POAIPredictive Oncology$1.66M14.44N/AN/A($0.46) per share-15.39RVPRetractable Technologies$37.15M0.59$0.02 per share48.25$3.31 per share0.22XAIRBeyond Air$7.68M0.88N/AN/A$3.32 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/A13.00N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)POAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/ARVPRetractable Technologies-$7.01M-$0.21N/AN/AN/A-41.11%-17.15%-9.33%N/AXAIRBeyond Air-$33.25M-$4.40N/AN/AN/A-432.99%-350.00%-101.34%8/11/2026 (Estimated)Latest XAIR, POAI, CTSO, and RVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2026Q4 2026XAIRBeyond Air-$0.5667-$0.77-$0.2033-$0.77$2.30 million$1.91 million5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81POAIPredictive OncologyN/A0.010.01RVPRetractable Technologies0.018.575.92XAIRBeyond Air3.483.804.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%POAIPredictive Oncology9.04%RVPRetractable Technologies7.58%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.80%POAIPredictive Oncology1.21%RVPRetractable Technologies59.50%XAIRBeyond Air9.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.84 million57.94 millionOptionablePOAIPredictive Oncology303.39 million3.35 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionableXAIRBeyond Air7014.41 million12.97 millionOptionableXAIR, POAI, CTSO, and RVP HeadlinesRecent News About These CompaniesBeyond Air (XAIR) Q4 2026 Earnings Call TranscriptJune 26, 2026 | finance.yahoo.comBeyond Air Inc (XAIR) Q4 2026 Earnings Call Highlights: Revenue Surge and Path to ProfitabilityJune 26, 2026 | finance.yahoo.comBeyond Air, Inc. (XAIR) Q4 2026 Earnings Call TranscriptJune 26, 2026 | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate UpdateJune 26, 2026 | globenewswire.comBeyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and WebcastJune 22, 2026 | globenewswire.comBeyond Air, Inc. Schedules Special Meeting of Stockholders to Vote on Reverse Stock Split to Avoid Nasdaq DelistingJune 10, 2026 | quiverquant.comQBeyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special MeetingJune 10, 2026 | globenewswire.comBeyond Air Receives Nasdaq Hearing Panel Decision Granting Continued ListingJune 1, 2026 | globenewswire.comBeyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026April 20, 2026 | globenewswire.comLucid, Beyond Air, Conagra stocks hit 52-week lows: What's behind the drag?April 16, 2026 | msn.comBeyond Air Appeals Nasdaq Notice on Listing ComplianceApril 15, 2026 | tipranks.comBeyond Air to Participate in the D. Boral Capital Global Conference 2026April 15, 2026 | globenewswire.comBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)April 1, 2026 | markets.businessinsider.comBeyond Air Names Robert Goodman as New CEOApril 1, 2026 | tipranks.comBeyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEOMarch 26, 2026 | markets.businessinsider.comBeyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO TrialMarch 17, 2026 | globenewswire.comBeyond Air to Participate in the 38th Annual Roth Conference in MarchMarch 11, 2026 | markets.businessinsider.comBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.March 10, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Beyond Air (XAIR)March 8, 2026 | theglobeandmail.comBeyond Air Inc (XAIR) Expands Focus on Nitric Oxide TherapiesMarch 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, POAI, CTSO, and RVP Company DescriptionsCytosorbents NASDAQ:CTSO$0.39 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.40 +0.01 (+2.31%) As of 07/2/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Predictive Oncology NASDAQ:POAI$7.08 -0.14 (-1.94%) As of 07/2/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Retractable Technologies NYSE:RVP$0.73 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$0.73 0.00 (-0.15%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.Beyond Air NASDAQ:XAIR$0.47 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.45 -0.02 (-3.85%) As of 07/2/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
